Cidon E Una
Oncology Department, Royal Bournemouth Hospital NHS Foundation Trust, Bournemouth, UK.
Clin Med Insights Oncol. 2016 May 12;10:43-8. doi: 10.4137/CMO.S32821. eCollection 2016.
Cholangiocarcinoma is a very heterogeneous and rare group of neoplasms originating from the perihilar, intra-, or extrahepatic bile duct epithelium. It represents only 3% of gastrointestinal cancers, although their incidence is increasing as its mortality increases. Surgical resection is the only potentially curative option, but unfortunately the resectability rate is low. Overall, these malignancies have got a very poor prognosis with a five-year survival rate of 5-10%. Although the five-year survival rate increases to 25-30% in the cases amenable to surgery, only 10-40% of patients present with resectable disease. Therefore, it is necessary to optimize the benefit of adjuvant strategies after surgery to increase the rate of curability. This study reviewed the role of adjuvant chemotherapy in resectable bile duct cancers.
胆管癌是一组起源于肝门周围、肝内或肝外胆管上皮的非常异质性且罕见的肿瘤。它仅占胃肠道癌症的3%，尽管随着其死亡率的增加发病率也在上升。手术切除是唯一潜在的治愈选择，但不幸的是可切除率很低。总体而言，这些恶性肿瘤的预后非常差，五年生存率为5%至10%。尽管在适合手术的病例中五年生存率提高到25%至30%，但只有10%至40%的患者表现为可切除疾病。因此，有必要优化术后辅助治疗策略的益处以提高治愈率。本研究回顾了辅助化疗在可切除胆管癌中的作用。
